Testing the drug RVU120, alone and with everolimus, in children whose medulloblastoma came back or grew
Original title: Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests how safe a drug called RVU120 is for children with medulloblastoma that came back or kept growing.
Who this trial is for. This trial is for children with group 3 or group 4 medulloblastoma that has come back or is growing. It tests a drug called RVU120 by itself and together with another drug, everolimus.
Where it stands. The trial has not reported results. It is measuring how safe the drugs are and how well children handle them. It is also meant to give an early look at whether this approach helps. That answer is not in yet.
What this means, and what it doesn't
What it could mean: If your child fits this picture, you could ask their care team about this study. The team can walk you through the possible risks and whether it makes sense for your child.
What it doesn't mean: This does not mean the drugs work. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.